[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Linke R, Klein A, Seimetz D: Catumaxomab: clinical development and future directions. MAbs; 2010 Mar-Apr;2(2):129-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites.
  • The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab(®)) together with its partner TRION Pharma GmbH, Germany.
  • It is the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas.
  • Since the peritoneum is of mesothelial origin and therefore lacks EpCAM expression, the intraperitoneal administration of catumaxomab is an attractive targeted immunotherapeutic approach.
  • Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites.
  • In addition, catumaxomab is a potential therapeutic option for several primary tumors since the EpCAM molecule is expressed on the majority of epithelial carcinomas.
  • [MeSH-major] Antibodies, Bispecific / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Immunotherapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, Neoplasm / immunology. Cell Adhesion Molecules / immunology. Drug Discovery. Epithelial Cell Adhesion Molecule. European Union. Humans. Immunomodulation

  • Guide to Pharmacology. gene/protein/disease-specific - CD molecules - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - CD3e - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5627-9 [19584271.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2526-34 [11588051.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Cell Adhes Commun. 1994 Oct;2(5):417-28 [7842256.001]
  • [Cites] J Immunol. 1995 Jul 1;155(1):219-25 [7602098.001]
  • [Cites] Scand J Immunol. 1996 Aug;44(2):157-63 [8711429.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1246-52 [10415020.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):397-405 [15864281.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):128-35 [16404366.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3085-91 [16707606.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):349-56 [17431406.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Cancer Immunol Immunother. 2007 Oct;56(10):1637-44 [17410361.001]
  • [Cites] Cancer Immunol Immunother. 2009 Mar;58(3):317-24 [18704409.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):195-202 [19238019.001]
  • [Cites] J Histochem Cytochem. 2001 Jul;49(7):911-7 [11410615.001]
  • (PMID = 20190561.001).
  • [ISSN] 1942-0870
  • [Journal-full-title] mAbs
  • [ISO-abbreviation] MAbs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / Epithelial Cell Adhesion Molecule; 0 / catumaxomab
  • [Other-IDs] NLM/ PMC2840231
  •  go-up   go-down


2. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J: Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer; 2006 Nov 1;107(9):2108-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.
  • Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course.
  • The authors present a comprehensive review of the literature on HEH with a focus on clinical outcome after different therapeutic strategies.
  • The reviewed parameters included demographic data, clinical manifestations, therapeutic modalities, and clinical outcome.
  • Most patients presented with multifocal tumor that involved both lobes of the liver.
  • Lung, peritoneum, lymph nodes, and bone were the most common sites of extrahepatic involvement at the time of diagnosis.
  • The most common management has been liver transplantation (LTx) (44.8% of patients), followed by no treatment (24.8% of patients), chemotherapy or radiotherapy (21% of patients), and liver resection (LRx) (9.4% of patients).
  • The 1-year and 5-year patient survival rates were 96% and 54.5%, respectively, after LTx; 39.3% and 4.5%, respectively, after no treatment, 73.3% and 30%, respectively, after chemotherapy or radiotherapy; and 100% and 75%, respectively, after LRx.
  • LRx has been the treatment of choice in patients with resectable HEH.
  • However, LTx has been proposed as the treatment of choice because of the hepatic multicentricity of HEH.
  • The role of different adjuvant therapies for patients with HEH remains to be determined.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Hepatectomy. Humans. Liver Transplantation. Male. Neoplasm Metastasis. Survival Rate

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019735.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


3. Kinderyte R, Alisauskaite L, Juodzbaliene EB, Juozaityte E: [Angiosarcoma of the breast: a case report and literature review]. Medicina (Kaunas); 2006;42(7):580-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcoma of the breast is a rare tumor (makes up 0.5 to 1% of all malignant breast tumors).
  • In literature, only isolated cases of primary angiosarcoma of the breast were described.
  • The tumor in the breast was diagnosed after breast trauma.
  • Nine months after surgery tumor spread was observed in subdermal layer, lymph nodes, and lungs.
  • The effect of chemotherapy and radiotherapy was only partial and short.
  • The tumor extended further to the lungs, pleura, and peritoneum.
  • A patient from the time of diagnosis survived for 8 months.
  • The mean survival of patients with angiosarcoma of the breast, described in literature, ranges from 13 to 22 months, and the treatment in this case most likely could not have an effect on survival of the patient.
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Mastectomy, Simple. Prognosis. Radiography, Thoracic. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861841.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


Advertisement
4. Ahmed N, Oliva K, Rice GE, Quinn MA: Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res; 2004 Apr 1;10(7):2415-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have examined the expression of cell-free 59 kDa immunoreactive (ir)ILK in the serum and peritoneal fluid (PTF) of patients with ovarian cancer and evaluated its potential as a serum biomarker for early-stage screening and for monitoring clinical status of patients after chemotherapy treatment.
  • In addition, tissue-conditioned medium obtained from the cultures of primary ovarian tumors (n = 9) was examined for the presence of irILK.
  • Finally, the potential of serum irILK as a biomarker for ovarian cancer screening was evaluated by comparison with cancer antigen 125 (CA 125) concentrations in cancer patients before and after chemotherapy.
  • Tissue-conditioned medium prepared from malignant ovarian tumors had 4-fold more irILK expression than conditioned medium obtained from borderline and benign tumors (P < 0.01).
  • irILK expression in serum of cancer patients was reduced to basal normal levels after six cycles of Taxol/carboplatin and was consistent with the change of CA 125 levels before and after chemotherapy.
  • CONCLUSIONS: These data suggest that irILK is an ovarian tumor-associated antigen and implicates its potential not only as a biomarker for early-stage screening but also as a marker for monitoring the clinical condition of patients after treatment.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis
  • [MeSH-minor] Blotting, Western. CA-125 Antigen / biosynthesis. Cell-Free System. Culture Media, Conditioned. Female. Humans. Peritoneum / metabolism. Time Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15073119.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Culture Media, Conditioned; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


5. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol; 2003 Oct;129(10):549-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
  • Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration.
  • Afterwards, chemotherapy was administered through a peritoneal catheter.
  • Diagnoses were: malignant mesothelioma (six patients), signet ring cell (three), colon adenocarcinoma, pseudomyxoma peritonei, gastrointestinal stromal tumor (two each), and ovarian carcinoma (one).
  • Peri-operative complications included one colonic perforation requiring primary closure, a peritoneal catheter malfunction, a port site hematoma, and an ascites leak requiring re-suture.
  • Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment.
  • Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adult. Aged. Area Under Curve. Ascites / metabolism. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / metabolism. Female. Humans. Injections, Intraperitoneal. Liposomes. Male. Mesothelioma / drug therapy. Mesothelioma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Peritoneum / diagnostic imaging. Peritoneum / metabolism. Radionuclide Imaging. Technetium. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4509-12 [3396003.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):315-7 [1879050.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58 [8202717.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503 [12107555.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] J Med Chem. 1991 Jan;34(1):325-9 [1992134.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):131-42 [417410.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):21-6 [3039867.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):1-8 [2720887.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8 [4048973.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):323-9 [8458256.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4254-9 [2364384.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3944-6 [12351590.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):65-71 [2104572.001]
  • (PMID = 14513369.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II); 7440-26-8 / Technetium
  •  go-up   go-down


6. Alanbay I, Dede M, Ustün Y, Karaşahin E, Deveci S, Günhan O, Yenen MC: Serous psammocarcinoma of the ovary and peritoneum: two case reports and review of the literature. Arch Gynecol Obstet; 2009 Jun;279(6):931-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous psammocarcinoma of the ovary and peritoneum: two case reports and review of the literature.
  • Serous psammocarcinoma (SPC) is a rare variant of ovarian carcinoma or peritoneum that may present with features consistent with malignancy, or tumors of low malignant potential.
  • This is two-case reports of a SPC of the ovary and peritoneum and review of the literature.
  • Histological examination revealed endometrioma and psammocarcinoma of the peritoneum.
  • She received six courses of chemotherapy.
  • She has no evidence of disease after 6 years from surgical therapy and chemotherapy.
  • CT scan showed extensive tumor in the lower abdomen, and free fluid in the abdomen and pelvis which appeared to be an ovarian tumor.
  • She underwent a laparotomy and a right and left ovarian tumor measuring about 20 x 15 and 8 x 8 cm, respectively, were seen.
  • Staging procedure was performed.
  • Chemotherapy was planned.
  • Primary surgical debulking should be attempted, while the utility of postoperative chemotherapy remains unknown.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982336.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 29
  •  go-up   go-down


7. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • We describe the clinicopathologic features of two cases diagnosed as CCC of the peritoneum origin.
  • Case 2, a 66-year-old woman, presented with massive ascites and abdominal tumor.
  • The ovaries and uterine endometrium of these cases were not affected, and the tumors were diagnosed as Stage IIIc CCC of the peritoneum origin.
  • Adjuvant chemotherapy using irinotecan and cisplatin was effective in one case.
  • The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


8. Cotte E, Passot G, Isaac S, Gilly FN, Glehen O: [Malignant primary peritoneal tumors]. Presse Med; 2009 Dec;38(12):1814-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary peritoneal tumors].
  • Malignant primary peritoneal tumors are rare and should be kept in mind when peritoneal carcinomatosis is diagnosed without primary tumor found.
  • The principal etiologies are peritoneal mesthelioma, pseudomyxoma peritonei and primary peritoneal serous carcinoma.
  • Their diagnosis requires most of the time biopsy performing by laparoscopy that should prevent tumoral parietal diffusion (port sites on the middle line).
  • The treatment of reference combines optimal cytoreductive surgery and perioperative intraperitoneal chemotherapy when general status allows performing it.
  • The management of these diseases should be done into specialized centers, included into national network (RENAPE), because of specificity and complexicity of treatments and to facilitate clinical and fundamental research on rare disease.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cancer Care Facilities. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / drug therapy. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasm Staging. Peritoneum / pathology. Prognosis. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356892.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


9. Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC: Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncol; 2005;44(7):756-60
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature.
  • Malignant mixed mullerian tumors (MMMTs), also known as carcinosarcoma because they contain both carcinomatous and sarcomatous elements are aggressive tumors, which usually arise in the uterus and ovary.
  • Extragenital carcinosarcomas are extremely rare and most cases develop from the peritoneum.
  • Here we report a case of a primary carcinosarcoma of the pelvic peritoneum with five-year disease-free survival after managing the patient with surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinosarcoma / diagnosis. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Mullerian / diagnosis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Laparotomy. Middle Aged. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227168.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Takeyoshi I, Iwanami K, Yamada T, Kawate S, Hamada K, Sunose Y, Yoshida M, Horiguchi J, Ohwada S, Sasaki A, Morishita Y: Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report. Hepatogastroenterology; 2005 Jan-Feb;52(61):322-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography demonstrated a thickening of the gastric wall, severe ascites, and peritoneal dissemination in the Douglas pouch.
  • By completion of the first course of treatment, the ascites had disappeared, the tumor in the Douglas pouch had shrunk, and the thickening of the gastric wall had lessened.
  • In addition, the fold in the stomach appeared by endoscopic examination to have resumed its normal thickness, no malignant cells were detected in a biopsy, and the thymidine phosphorylase activity in the tumor tissue was two-fold greater than that before chemotherapy.
  • After three treatment courses, the number of apoptotic cells had apparently increased compared with the prechemotherapy number.
  • The only adverse drug reactions that were observed were grade 2 alopecia and grade 1 myalgia.
  • After thirteen courses of chemotherapy over the past one year, both primary and metastatic lesions seem to be regressing.
  • This case study suggests that paclitaxel plus doxifluridine therapy is effective and well-tolerated in non-resectable gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Female. Floxuridine / administration & dosage. Humans. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Pentosyltransferases / metabolism. Peritoneum / pathology. Pyrimidine Phosphorylases

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783060.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 039LU44I5M / Floxuridine; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.- / Pyrimidine Phosphorylases; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


11. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, Wang JY: Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol; 2008;29(3):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review.
  • Malignant mixed müllerian tumor (MMMT) is a rare tumor in females and extragenital MMMT is even more so.
  • Furthermore, among the cases reviewed, MMMTs tend to be associated with synchronous or metachronous colonic cancer or gynecologic tumors originating from the müllerian duct, including ovarian tumors, fallopian tube cancer, endometrial cancer, cervical cancer, and serous carcinoma of the peritoneum (14 out of 43 patients; 32.6%).
  • The prognosis of MMMT is catastrophic and the treatment is based on the experience of those of uterine sarcomas, which is composed of operation, radiotherapy and chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Mesentery / pathology. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Postmenopause


12. Salemis NS, Gourgiotis S, Tsiambas E, Panagiotopoulos N, Karameris A, Tsohataridis E: Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor. J Gastrointest Cancer; 2010 Dec;41(4):238-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor.
  • BACKGROUND AND PURPOSE: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life occurring predominantly in the extremities.
  • Primary intra-abdominal MFH is a very rare occurrence.
  • Computed tomography (CT) scan demonstrated a mass in the right iliac fossa.
  • RESULTS: On exploratory laparotomy, a tumor was found in the right iliac fossa attached to the parietal lateral peritoneum without any evidence of invasion into the adjacent structures.
  • Complete excision of the tumor with clear margins was performed.
  • One month after surgery, while on adjuvant chemotherapy, the patient was readmitted with dyspnea and a slightly palpable mass in the area of the previous radical resection.
  • CT scan revealed local tumor recurrence along with multiple pulmonary metastatic deposits.
  • Unfortunately, despite treatment, the patient died of progressive disease 5 weeks later.
  • CONCLUSIONS: Primary intra-abdominal MFH is a very rare but aggressive malignancy with a high tendency of local recurrence and metastatic spread.
  • Early detection and complete surgical excision with clear margins is the treatment of choice.
  • In some cases, however, the tumor can exhibit a highly aggressive clinical course despite radical surgery and adjuvant therapy.
  • [MeSH-major] Abdomen / pathology. Histiocytoma, Malignant Fibrous / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):499-505 [1845950.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2098-103 [1311983.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1299-302 [17451221.001]
  • [Cites] Gastrointest Radiol. 1988 Oct;13(4):299-305 [2844619.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Surg Today. 2003;33(10 ):794-6 [14513333.001]
  • [Cites] Surg Today. 2002;32(12):1091-5 [12541030.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] World J Gastroenterol. 2007 Dec 21;13(47):6441-3 [18081238.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Clin Imaging. 1998 Nov-Dec;22(6):408-13 [9876909.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Dig Surg. 1999;16(5):425-30 [10567806.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 22;3:15 [16792809.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):105-12 [16648661.001]
  • (PMID = 20419356.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Haibin Z, Yue J, Yaxian X: Primary yolk sac tumor of the omentum: a case report and literature review. Eur J Gynaecol Oncol; 2010;31(6):682-4
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the omentum: a case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is the second most common malignant ovarian germ cell tumor, while a YST arising in the omentum is an exceedingly rare malignancy.
  • The patient was treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy and infracolic omentectomy followed by four cycles of bleomycin, etoposide, and cisplatin combination chemotherapy.
  • She has remained free of the disease for seven months after completion of therapy.
  • CONCLUSION: This is the fourth case of primary omental YST in females.
  • The case of omental YST must be seriously considered once the tumor shows omentum thickening with elevated AFP serum levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Omentum / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Hysterectomy. Ovariectomy. Peritoneum / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319517.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


14. Markaki S, Protopapas A, Milingos S, Lazaris D, Antsaklis A, Michalas S: Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study. Gynecol Oncol; 2005 Mar;96(3):860-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study.
  • BACKGROUND: Primary peritoneal mesothelioma is regarded as a fatal disease that presents with progressive ascites at a relatively late stage of its natural history.
  • Differential diagnosis between this rare tumor and both serous papillary carcinoma of the peritoneum and ovary can be problematic.
  • Exploratory laparotomy revealed the presence of extensive intraperitoneal dissemination of a malignant neoplasm without a recognizable primary site.
  • Suboptimal cytoreduction was carried out, and histological diagnosis was that of a malignant epithelioid mesothelioma.
  • The patient despite having a complete response after adjuvant chemotherapy died 18 months after primary surgery.
  • CONCLUSION: No single immunohistochemical stain is pathognomonic of peritoneal primary malignant mesothelioma (PMM), and the results of a panel of antibodies should be interpreted to set the diagnosis.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721439.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sticca RP, Dach BW: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am; 2003 Jul;12(3):689-701

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.
  • Hyperthermia is selectively cytotoxic for malignant cells due to inhibition of oxidative metabolism causing lower pH in the microenvironment of the malignant cells and tumor.
  • Hyperthermia alone as a primary treatment modality for malignancy has largely been abandoned due to high morbidity and mortality and high recurrence rates.
  • Advances in administration and monitoring of hyperthermia, especially for regional applications, has allowed for the use of hyperthemia in conjunction with other modalities of antineoplastic therapy.
  • Hyperthermia has been shown to potentiate chemotherapy and radiation by several different mechanisms.
  • HIIC uses the advantages of hyperthermia in conjunction with chemotherapy for the management of peritoneal carcinomatosis.
  • Several different chemotherapy agents have been shown to have improved therapeutic index and efficacy when used with hyperthermia in the management of peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hyperthermia, Induced / methods. Infusions, Parenteral. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy. Peritoneum / surgery
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Models, Animal. Female. Humans. Intraoperative Period. Male. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14567025.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


16. Koutselini HA, Lazaris AC, Thomopoulou G, Papayannopoulou A, Kairi-Vasilatou E: Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors. Adv Clin Path; 2001 Jul;5(3):99-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
  • The distinction between malignant mesothelioma and other malignant neoplasms diffusely involving the peritoneum is important for proper patient treatment.
  • The extra-ovarian peritoneal serous papillary carcinoma is a rare, primary, multicentric peritoneal tumor that is morphologically identical to ovarian serous carcinoma of equivalent grade, but can spare or minimally involve the ovaries.
  • We report such a tumor in a 65-year-old female who had abdominal swelling, ascites with positive cytology and a high grade of nuclear atypia in malignant cells as well as elevated serum CA125.
  • Exploratory laparotomy findings of intrabdominal carcinomatosis were not accompanied by any evident primary site; so the diagnosis of a primary papillary serous neoplasia of the peritoneum was strongly considered.
  • Since the amount of residual disease may be an important prognostic determining factor in primary papillary serous carcinoma of the peritoneum, the patient was debulked to no macroscopic disease and was then given platin-based chemotherapy.
  • The tumor's differential diagnosis from malignant mesothelioma was based, apart from morphologic criteria, on the tumor's immunoreactivity to MOC-31, Ber-EP4 and TAG-72, as well as on the lack of immunostaining for keratin 5/6 and calretinin.
  • Differential diagnosis from ovarian cancer was possible only after the pathological examination of the surgically resected ovaries; the tumor showed minimal superficial invasion of the ovarian cortex.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Diagnosis, Differential. Female. Humans. Mesothelioma / pathology. Ovarian Neoplasms / pathology. Paclitaxel / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753882.001).
  • [ISSN] 1125-5552
  • [Journal-full-title] Advances in clinical pathology : the official journal of Adriatic Society of Pathology
  • [ISO-abbreviation] Adv Clin Path
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Jähne J: [Principle and indications for debulking operation in peritoneal carcinosis]. Kongressbd Dtsch Ges Chir Kongr; 2001;118:209-12
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies demonstrate that cytoreductive surgery (debulking) is a feasible option for the treatment of peritoneal carcinomatosis.
  • Indications for such an approach, often combined with intraperitoneal chemotherapy, are malignant conditions of the appendix, the colon, the ovary and peritoneal mesothelioma.
  • The operation itself consists of complete peritonectomy of the parietal peritoneum, multivisceral resection including cholecystectomy, gastric and colonic resection as well as anterior rectal resection.
  • Depending on the histology of the primary tumor, 5 years survival rates of up to 50-75% can be achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824248.001).
  • [Journal-full-title] Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress
  • [ISO-abbreviation] Kongressbd Dtsch Ges Chir Kongr
  • [Language] GER
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Gopaldas R, Kunasani R, Plymyer MR, Bloch RS: Hepatoid malignancy of unknown origin--a diagnostic conundrum: review of literature and case report of collision with adenocarcinoma. Surg Oncol; 2005 Jul;14(1):11-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiating these tumors is not only a challenge but also critical, since treatment modalities and operative strategies are dependent upon the exact nature of the hepatoid cancer.
  • Based on a review of literature, we discuss the guidelines for differentiating these tumors and utilize these criteria to differentiate these tumors irrespective of their primary tissue of origin.
  • We also describe an unusual case of hepatoid variant of primary peritoneal yolk sac tumor presenting with extensive carcinomatosis and as a collision with two synchronous primary colonic adenocarcinomas, neither of which has been reported to our knowledge to date, thereby falsely mimicking metastatic dedifferentiated colonic adenocarcinoma.
  • A work up which included computed tomography (CT) and contrast enema revealed significant ascites with multiple peritoneal nodules causing ascending colonic obstruction.
  • Intraoperative ultrasound, prompted by the frozen section of nodules resembling liver tissue, revealed no intrahepatic nodules.
  • Right colectomy, omentectomy and tumor debulking were performed.
  • DISCUSSION: The peritoneal nodules consisted of malignant cells arranged in cords that resembled liver tissue.
  • In the absence of a primary identifiable liver disease, this is consistent with either hepatoid variant of primary yolk sac tumor or hepatoid carcinoma arising from the peritoneum.
  • The right colectomy specimen revealed two mucosal ulcers consistent with colonic adenocarcinoma abutting two large tumor nodules on the serosal surface.
  • Immunohistochemical stains and patterns were used to differentiate the type of tumor.
  • CONCLUSION: The most likely explanation in our case is that the hepatoid tumor either originated from microscopic remnant ovarian tissue left behind or primarily from the peritoneum.
  • With no evidence of yolk sac component within the colonic tumor or in the draining lymphatics, this essentially excludes the commonly observed metastatic dedifferentiation (opisthoplasia) of adenocarcinoma to primitive forms (also known as combination tumors).
  • Based on analysis of various factors, including tumor behavior and response to chemotherapy, we conclude that our case was a hepatoid variant of yolk sac tumor presenting in an elderly woman with carcinomatosis.
  • This unusual presentation of two entirely different primary malignancies in close proximity is defined as "collision tumor".
  • This is the first reported case of collision tumors involving dual colonic and primary peritoneal hepatoid-YST.
  • Identifying the exact type still remains to be the most challenging aspect in the diagnosis of hepatoid tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Endodermal Sinus Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777886.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 52
  •  go-up   go-down


19. Akbulut M, Kelten C, Bir F, Soysal ME, Duzcan SE: Primary peritoneal serous psammocarcinoma with recurrent disease and metastasis: a case report and review of the literature. Gynecol Oncol; 2007 Apr;105(1):248-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal serous psammocarcinoma with recurrent disease and metastasis: a case report and review of the literature.
  • BACKGROUND: Psammocarcinoma is a rare variant of serous carcinoma arising from either ovary or peritoneum.
  • Although behavior of tumor is uncertain, it has been suggested to be similar to serous carcinomas of low malignant potential.
  • Computed tomography showed a heavily calcified rectovaginal mass that was histologically characterized by numerous psammoma bodies and low-grade cytological features.
  • Following the primary surgery, the patient received 9 cycles of chemotherapy.
  • CONCLUSION: Although psammocarcinoma is known to behave in a more indolent course, clinicians should be aware that patients with this disease may have a clinically aggressive, recurrent, and metastatic tumor that necessitated systemic therapy.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Neoplasm Recurrence, Local / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222893.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Noguchi T, Kawamura M, Kawamura T, Shimamura T, Sasaki K, Hosono T, Sato R, Murakami K: [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1975-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites].
  • Abdominal CT revealed vast ascites but there was no obvious primary lesion.
  • Serum tumor markers and hyaluronate were within the normal range.
  • We suspected diffuse malignant peritoneal mesothelioma because hyaluronate in ascites rose to 10×10⁴ ng/mL.
  • We performed laparoscopic observation for definite diagnosis and found fine white particles at the peritoneum.
  • The result of biopsy was malignant mesothelioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948267.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Liu YC, Kuo YL, Yu CP, Wu HS, Yu JC, Chen CJ, Chan DC, Yu CY, Hsieh CB, Chen TW: Primary malignant mesothelioma of the greater omentum: report of a case. Surg Today; 2004;34(9):780-3
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesothelioma of the greater omentum: report of a case.
  • We report a rare case of primary malignant mesothelioma of the greater omentum.
  • Abdominal sonography and computed tomography showed a 12 x 9 x 9-cm(3) mass occupying the lower abdomen.
  • Laparotomy revealed a tumor in the greater omentum, invading the posterior wall of the uterus, without diffuse mesenteric thickening or multiple small nodules in the peritoneum.
  • Microscopically, the tumor cells were arranged in a tubulopapillary pattern lined by a single layer of uniform, cuboidal cells.
  • Immunohistochemically, the tumor cells showed strong positivity for calretinin.
  • The final pathologic diagnosis was malignant mesothelioma.
  • The patient did not receive chemotherapy or radiotherapy, and has remained in good health without any evidence of recurrence for almost 3 years since her operation.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Laparotomy. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15338355.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Bork K, Schreiber J, Bräuninger W: [Umbilical metastasis of a gallbladder carcinoma: "Sister Mary Joseph's nodule"]. Dtsch Med Wochenschr; 2002 Mar 15;127(11):553-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTOLOGY AND CLINICAL FINDINGS: A 63-year-old man presented with a firm and crusting umbilical mass which had developed within several weeks.
  • The tumor was 1.5 cm in diameter.
  • Physical examination was normal except the umbilical tumor.
  • INVESTIGATIONS: Histologic examination revealed a malignant epithelial tumor corresponding to a metastasis of an adenocarcinoma which could be a carcinoma of the gallbladder or the pancreas.
  • Initially the following clinical examination of the patient showed no pathological findings: gastroscopy and coloscopy gave no hint for a primary carcinoma.
  • Computed tomography of the abdomen revealed a thickened gallbladder wall with an irregular intraluminal contour suspicious of a gallbladder carcinoma.
  • There were numerous carcinomatous lesions on the peritoneum.
  • DIAGNOSIS, TREATMENT AND COURSE: Histologic examination revealed a metastatic adenocarcinoma of the gallbladder with tumorous infiltration of the liver tissue and a solitary metastasis in the skin (>>Sister Mary Joseph's nodule<<).
  • Following a recovery phase at home a palliative chemotherapy was planned.
  • Sonography revealed a hilar tumor measuring 4 cm in diameter.
  • The necessary examination and therapy including excision of the umbilical metastasis is warranted without delay.
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Cholecystectomy. Follow-Up Studies. Gallbladder / pathology. Humans. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11894175.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Kecmanović D, Kovacević P, Pavlov M, Sepetkovski A, Ceranić M: [Cytoreductive procedures in advanced primary ovarian carcinoma]. Acta Chir Iugosl; 2001;48(1):71-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytoreductive procedures in advanced primary ovarian carcinoma].
  • Female patient, 68, hospitalized due to vaginal bleeding, anaemia and defecation disorder.
  • Explorative curretage of uterus--PH findings: malignant tissue.
  • Irigography: spasticity and extraluminal compression to proximal third of rectum and distal sigmoid colon.
  • Ultrasound of liver: without signs of malignant disease.
  • CT-scan of pelvis and abdomen: metastatic lymph nodes, up to 40 mm in diameter, alongside abdominal aorta; solid-lobular tumor, 10 x 7 cm, on the left side of urinary bladder, which fills the central portion of pelvic cavum.
  • Secundary malignant deposits on the pelvic parietal peritoneum with minimal quantity of ascites (peritoneal carcinomatosis).
  • Intraoperative findings confirmed malignant deposits on the right colon serosa, so we performed right hemicolectomy with ileo-colo anastomosis, omentectomy, hysterectomy, bilateral adnexectomy, low anterior resection of the rectum, peritonectomy of pelvis and reconstruction of digestive tubus by colo-rectal anastomosis with circular stapler ILS 33.
  • One month after the operation, systemic chemotherapy consisting of Endoxan and Karboblastin was administered, for the duration of 6 months, once monthly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432258.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  •  go-up   go-down






Advertisement